Use of Different Tissue Thromboplastins in the Control of Anticoagulant Therapy
- 1 August 1957
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 16 (2) , 213-226
- https://doi.org/10.1161/01.cir.16.2.213
Abstract
As anticoagulant therapy has become more widespread and a greater knowledge has been accumulated regarding the mode of action of coumarin derivatives, problems arising from the use of different thromboplastin preparations have been subjected to greater scrutiny. This paper presents an evaluation of the dependability and significance of different types of tissue thromboplastin in the determination of effects of coumarin derivatives. The main difference between thromboplastin extracts seems to be that brain preparations have a factor VII-like activity. As the exact evaluation of factor VII activity appears to be of primary importance in patients treated with coumarin derivatives, a thromboplastin preparation that does not contain factor VII activity is recommended.Keywords
This publication has 6 references indexed in Scilit:
- Technical Objectives in the Control of Anticoagulant TherapyBritish Journal of Haematology, 1955
- THE COAGULATION DEFECT CAUSED BY TROMEXAN THERAPY1955
- The Clotting Action of Russell Viper VenomBlood, 1954
- Electrokinetic studies on fibrinogen. III. The effect of concentration, pH and surface on the fibrinogen-solid interfacial potentialArchives of Biochemistry and Biophysics, 1954
- The Control of Dicumarol Therapy and the Quantitative Determination of Prothrombin and ProconvertinScandinavian Journal of Clinical and Laboratory Investigation, 1951